Table 1.
Information on the design of national and regional CRC screening programs, and local CRC rates and participation rates.
| Countrya | Age-standardised CRC rates per 100,000 persons |
Screening program |
|||||
|---|---|---|---|---|---|---|---|
| Incidence49 | Mortality49 | Screening age range (years) | Screening interval | Screening categoryb | Status quo screening rate/volume (year)c | Sources | |
| Australia | 33.1 | 8.9 | 50–74 | Biennial | 3 | 43.5% (2019) | 21,50 |
| Belgiumd | 35.3 | 10 | 50–74 | Biennial | 3 | 31.1% (2019) | 51,52 |
| Canada | 31.2 | 9.9 | 50–74 | Biennial | 3 | 42.9% (2017) | 53 |
| Croatia | 36.3 | 19.6 | 50–74 | Biennial | 3 | 15.3% (2014) | 51,54 |
| Czechia | 33.7 | 12.3 | 50−f,g | Biennial | 3 | 30.1% (2019) | 55 |
| Denmark | 40.9 | 11.8 | 50–74 | Biennial | 3 | 60.3% (2019) | 56 |
| France | 30.1 | 10.4 | 50–74 | Biennial | 3 | 30.5% (2019) | 57 |
| Georgia | 15.6 | 8.3 | 50–69 | Biennial | 2 | 74.7% (2015) | 58,59 |
| Germanye | 25.8 | 9.9 | 50−f | Biennialg | 3 | 51.0% (2016) | 60 |
| Hungary | 45.3 | 20.2 | 50–70 | Biennial | 2 | 36.7% (2013) | 51,54 |
| Iceland | 28.5 | 9.5 | 55–75 | Biennial | 2 | 30.0% (2015) | 51,61 |
| Ireland | 34.9 | 12.4 | 60–69 | Biennial | 4 | 112,077h (2018/9) | 62 |
| Israel | 21.9 | 9.0 | 50–74 | Annual | 1 | 1,026,579h (2019) | 63 |
| Italyi | 29.3 | 10.1 | 50–69 | Biennial | 2 | 43.5% (2019) | 64,36 |
| Japan | 38.5 | 11.6 | 40−f | Annual | 1 | 13.8%j (2019) | 65, 66, 67, 68 |
| Lithuania | 27.6 | 11.7 | 50–74 | Biennial | 3 | 17.9% (2018) | 69 |
| Malta | 25.7 | 10.1 | 55–66 | Biennial | 4 | 35.7% (2013) | 51,54 |
| Netherlands | 41.0 | 13.5 | 55–75 | Biennial | 2 | 71.8% (2019) | 70 |
| Portugal, Alentejo and Centro | 39.4 | 13. | 50–69 | Biennial | 2 | 62.8% (2014) | 54 |
| Portugal, Norte | 39.4 | 13. | 50–69 | Biennial | 2 | 29.% (2019) | 71 |
| Singapore | 33.0 | 16.2 | 50−f | Annual | 1 | 27.3% (2016) | 72,73 |
| Slovakia | 43.9 | 21. | 50–74 | Biennial | 3 | 34.0% (2019) | 74 |
| Slovenia | 39.6 | 11.7 | 50–74 | Biennial | 3 | 50.5% (2012) | 60 |
| South Korea | 27.2 | 7.8 | 50–80 | Annual | 1 | 19.1% (2019) | 75 |
| Spaink | 35.8 | 11.5 | 50–69 | Biennial | 2 | 52.9% (2019) | 76,77 |
| Sweden | 27.8 | 10.8 | 60–69 | Biennial | 4 | 68.4% (2016) | 51,78 |
| Switzerland | 22.3 | 7.5 | 50–69 | Biennial | 2 | 16,377h (2014) | 79 |
| Taiwanl | 26.480 | 11.280 | 50–74 | Biennial | 3 | 1,180,000h (2016) | 81 |
| UK–Englandm | 34.1 | 11.4 | 60–74 | Biennial | 4 | 62.4% (2019) | 82 |
| UK—N. Irelandm | 34.1 | 11.4 | 60–74 | Biennial | 4 | 59.4% (2017) | 83 |
| UK–Scotlandm | 34.1 | 11.4 | 50–74 | Biennial | 3 | 63.0% (2019) | 84 |
| UK–Walesm | 34.1 | 11.4 | 58–74 | Biennial | 4 | 58.9% (2019) | 85 |
| Uruguay | 32 | 14.3 | 50–69 | Biennial | 2 | 42.0% (2019) | 86 |
Abbreviations: CRC, Colorectal cancer; UK, United Kingdom.
For Luxembourg, Montenegro, and New Zealand, it was established that there was an organised screening program, but no data was identified on the participation rates in these programs; they were excluded from the analysis.
See Supplementary Table S1. Closest screening category identified to be used in modelling, based on screening interval, start age, and number of lifetime screens.
The year noted is the most recent year prior to 2019 with complete screening data available at the time of review.
Based on data from Flanders, Wallonia, and Brussels regions.
Also offers organized colonoscopy screening; for the purposes of this study, only faecal screening has been included.
No official screening stop age.
Screening is offered annually from ages 50–54.
Where screening is provided as screening volume (number of participants) in official sources rather than participation rate, this has been replicated here.
Calculated from data available by regional programs.
Based on data from municipal screening, as screening participation rates were not available for workplace-based screening. Workplace-based screening is likely to have higher participation rates, but up-to-date data is unavailable.
Calculated from data available for regional programs in Barcelona, Basque Country, Valencia, and Catalonia.
GloboCan data on incidence and mortality was not available for Taiwan.
For England, Northern Ireland, Scotland, and Wales, local screening program data was used, and CRC incidence rates and mortality ASRs were overall United Kingdom rates from GloboCan.